{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:18:50Z","timestamp":1791357530804,"version":"4.3.1"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company Ltd.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,10,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Sexual dysfunction is common with serotonergic antidepressants, including selective serotonin reuptake inhibitors (SSRIs) and serotonin\u2013norepinephrine reuptake inhibitors (SNRIs), and does not resolve in most patients. Vortioxetine, an antidepressant with a multimodal mechanism of action, has shown low rates of sexual dysfunction in previous major depressive disorder (MDD) trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>This study compared the effects of vortioxetine and escitalopram on sexual functioning in adults with well-treated MDD experiencing treatment-emergent sexual dysfunction (TESD).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Participants treated with, and responding to, citalopram, paroxetine, or sertraline were randomized to switch to either vortioxetine (10\/20\u2009mg; n\u2009=\u2009225) or escitalopram (10\/20\u2009mg; n\u2009=\u2009222) for 8 weeks. Sexual function was assessed using the Changes in Sexual Functioning Questionnaire Short Form (CSFQ-14), and antidepressant efficacy was assessed using the Montgomery-\u00c5sberg Depression Rating Scale (MADRS), Clinical Global Impressions (CGI) scale, and Profile of Mood States brief form (POMS-brief). Safety and tolerability were also assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measures<\/jats:title>\n                  <jats:p>The primary endpoint was change from baseline in the CSFQ-14 total score after 8 weeks of treatment. The MADRS, CGI, and POMS-brief were used to assess antidepressant efficacy. Safety was assessed via adverse events, vital signs, electrocardiograms, laboratory values, weight, and physical examination findings.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Vortioxetine showed significantly greater improvements in CSFQ-14 total score (8.8\u2009\u00b1\u20090.64, mean\u2009\u00b1\u2009standard error) vs. escitalopram (6.6\u2009\u00b1\u20090.64; P \u2009=\u20090.013). Benefits vs. escitalopram were significant on four of five dimensions and all three phases of sexual functioning assessed by the CSFQ-14 (P \u2009&amp;lt;\u20090.05). Antidepressant efficacy continued in both groups, with similar, but slight, improvements in MADRS and CGI scores. Vortioxetine and escitalopram had similar clinical efficacy profiles in this study, with safety profiles similar to previous trials. Nausea (n\u2009=\u20099, 4.0%) was the most common treatment-emergent adverse event leading to discontinuation of vortioxetine.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Switching antidepressant therapy to vortioxetine may be beneficial for patients experiencing sexual dysfunction during antidepressant therapy with SSRIs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/jsm.12980","type":"journal-article","created":{"date-parts":[[2015,9,2]],"date-time":"2015-09-02T17:35:49Z","timestamp":1441215349000},"page":"2036-2048","source":"Crossref","is-referenced-by-count":93,"title":["Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction"],"prefix":"10.1093","volume":"12","author":[{"given":"P. L.","family":"Jacobsen","sequence":"first","affiliation":[{"name":"Takeda Development Center Americas , Deerfield, IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. R.","family":"Mahableshwarkar","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas , Deerfield, IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Chen","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas , Deerfield, IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Chrones","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas , Deerfield, IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. H.","family":"Clayton","sequence":"additional","affiliation":[{"name":"University of Virginia , Charlottesville, VA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,10,1]]},"reference":[{"key":"2023010713375390400_bb0010","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/mpr.1359","article-title":"Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States","volume":"21","author":"Kessler","year":"2012","journal-title":"Int J Methods Psychiatr Res"},{"key":"2023010713375390400_bb0015","article-title":"Work group on major depressive disorder. Practice guideline for the treatment of patients with major depressive disorder","author":"American Psychiatric Association","year":"2010","edition":"third edition"},{"key":"2023010713375390400_bb0020","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1017\/S1092852900026729","article-title":"Sexual dysfunction in major depression","volume":"11","author":"Williams","year":"2006","journal-title":"CNS Spectr"},{"issue":"suppl 6","key":"2023010713375390400_bb0025","first-page":"33","article-title":"Major depressive disorder, antidepressants, and sexual dysfunction","volume":"67","author":"Clayton","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"2023010713375390400_bb0030","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/j.1743-6109.2009.01248.x","article-title":"Selective serotonin reuptake inhibitor-induced sexual dysfunction","volume":"6","author":"Corona","year":"2009","journal-title":"J Sex Med"},{"key":"2023010713375390400_bb0035","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/j.1743-6109.2007.00520.x","article-title":"Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder","volume":"4","author":"Clayton","year":"2007","journal-title":"J Sex Med"},{"key":"2023010713375390400_bb0040","doi-asserted-by":"crossref","first-page":"357","DOI":"10.4088\/JCP.v63n0414","article-title":"Prevalence of sexual dysfunction among newer antidepressants","volume":"63","author":"Clayton","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"2023010713375390400_bb0045","doi-asserted-by":"crossref","first-page":"686","DOI":"10.4088\/JCP.v66n0603","article-title":"Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder","volume":"66","author":"Delgado","year":"2005","journal-title":"J Clin Psychiatry"},{"issue":"suppl 3","key":"2023010713375390400_bb0050","first-page":"10","article-title":"Incidence of sexual dysfunction associated with antidepressant agents: A prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction","volume":"62","author":"Montejo","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"2023010713375390400_bb0055","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00004714-199902000-00013","article-title":"Effects of SSRIs on sexual function: A critical review","volume":"19","author":"Rosen","year":"1999","journal-title":"J Clin Psychopharmacol"},{"key":"2023010713375390400_bb0060","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/JCP.0b013e3181a5233f","article-title":"Treatment-emergent sexual dysfunction related to antidepressants: A meta-analysis","volume":"29","author":"Serretti","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"2023010713375390400_bb0065","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1177\/0269881109102779","article-title":"Prevalence and impact of antidepressant-associated sexual dysfunction in three European countries: Replication in a cross-sectional patient survey","volume":"24","author":"Williams","year":"2010","journal-title":"J Psychopharmacol"},{"key":"2023010713375390400_bb0070","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/00926239808404932","article-title":"Accommodation to serotonin reuptake inhibitor-induced sexual dysfunction","volume":"24","author":"Ashton","year":"1998","journal-title":"J Sex Marital Ther"},{"key":"2023010713375390400_bb0075","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1111\/j.1743-6109.2012.02769.x","article-title":"5-HT2A receptor-1438 G\/A polymorphism and serotonergic antidepressant-induced sexual dysfunction in male patients with major depressive disorder: A prospective exploratory study","volume":"9","author":"Liang","year":"2012","journal-title":"J Sex Med"},{"key":"2023010713375390400_bb0080","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1111\/j.1743-6109.2011.02256.x","article-title":"Female sexual dysfunction in patients treated with antidepressant-comparison between escitalopram and fluoxetine","volume":"9","author":"Sidi","year":"2012","journal-title":"J Sex Med"},{"key":"2023010713375390400_bb0085","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1517\/14740338.2014.951324","article-title":"Sexual dysfunction associated with major depressive disorder and antidepressant treatment","volume":"13","author":"Clayton","year":"2014","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"2023010713375390400_bb0090","article-title":"Strategies for managing sexual dysfunction induced by antidepressant medication","author":"Taylor","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2023010713375390400_bb0095","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2147\/DHPS.S7634","article-title":"Antidepressant-associated sexual dysfunction: Impact, effects, and treatment","volume":"2","author":"Higgins","year":"2010","journal-title":"Drug Healthc Patient Saf"},{"key":"2023010713375390400_bb0100","doi-asserted-by":"crossref","first-page":"E27","DOI":"10.1503\/jpn.130076","article-title":"Management strategies for SSRI-induced sexual dysfunction","volume":"38","author":"Rizvi","year":"2013","journal-title":"J Psychiatry Neurosci"},{"key":"2023010713375390400_bb0105","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3810\/pgm.2014.03.2744","article-title":"Antidepressants and sexual dysfunction: Mechanisms and clinical implications","volume":"126","author":"Clayton","year":"2014","journal-title":"Postgrad Med"},{"key":"2023010713375390400_bb0110","doi-asserted-by":"crossref","first-page":"772","DOI":"10.7326\/0003-4819-155-11-201112060-00009","article-title":"Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: An updated meta-analysis","volume":"155","author":"Gartlehner","year":"2011","journal-title":"Ann Intern Med"},{"key":"2023010713375390400_bb0115","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40264-013-0129-4","article-title":"Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: Results from a systematic review with network meta-analysis","volume":"37","author":"Reichenpfader","year":"2014","journal-title":"Drug Saf"},{"key":"2023010713375390400_bb0120","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1021\/jm101459g","article-title":"Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A novel multimodal compound for the treatment of major depressive disorder","volume":"54","author":"Bang-Andersen","year":"2011","journal-title":"J Med Chem"},{"key":"2023010713375390400_bb0125","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.euroneuro.2011.11.008","article-title":"A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD)","volume":"22","author":"Baldwin","year":"2012","journal-title":"Eur Neuropsychopharmacol"},{"key":"2023010713375390400_bb0130","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/YIC.0000000000000018","article-title":"Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20\u2009mg\/day: A randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder","volume":"29","author":"Boulenger","year":"2014","journal-title":"Int Clin Psychopharmacol"},{"key":"2023010713375390400_bb0135","doi-asserted-by":"crossref","first-page":"953","DOI":"10.4088\/JCP.11m07470","article-title":"A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder","volume":"73","author":"Henigsberg","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"2023010713375390400_bb0140","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1185\/03007995.2012.761600","article-title":"A randomized, double-blind trial of 2.5\u2009mg and 5\u2009mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder","volume":"29","author":"Mahableshwarkar","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"2023010713375390400_bb0145","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1007\/s00213-014-3839-0","article-title":"A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD","volume":"232","author":"Mahableshwarkar","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"key":"2023010713375390400_bb0150","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1017\/S1461145712000727","article-title":"A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5\u2009mg vortioxetine in adults with major depressive disorder","volume":"16","author":"Jain","year":"2013","journal-title":"Int J Neuropsychopharmacol"},{"key":"2023010713375390400_bb0155","article-title":"Lexapro [package insert]","year":"2011"},{"key":"2023010713375390400_bb0160","article-title":"M.I.N.I.: Mini International Neuropsychiatric Interview, English version 6.0.0 (DSM-IV)","author":"Sheehan","year":"2009"},{"key":"2023010713375390400_bb0165","first-page":"217","article-title":"Clinical Global Impressions (028-CGI)","volume-title":"ECDEU assessment manual for psychopharmacology","author":"Guy","year":"1976"},{"key":"2023010713375390400_bb0170","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/00926230500232909","article-title":"Reliability and construct validity of the Changes in Sexual Functioning Questionnaire short-form (CSFQ-14)","volume":"32","author":"Keller","year":"2006","journal-title":"J Sex Marital Ther"},{"key":"2023010713375390400_bb0175","first-page":"747","article-title":"Comparison of sexual functioning in clinical and nonclinical populations using the Changes in Sexual Functioning Questionnaire (CSFQ)","volume":"33","author":"Clayton","year":"1997","journal-title":"Psychopharmacol Bull"},{"key":"2023010713375390400_bb0180","first-page":"731","article-title":"The Changes in Sexual Functioning Questionnaire (CSFQ): Development, reliability, and validity","volume":"33","author":"Clayton","year":"1997","journal-title":"Psychopharmacol Bull"},{"key":"2023010713375390400_bb0185","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br J Psychiatry"},{"key":"2023010713375390400_bb0190","article-title":"EdITS manual for the profile of mood states","author":"McNair","year":"1971"},{"key":"2023010713375390400_bb0195","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: Initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am J Psychiatry"},{"key":"2023010713375390400_bb0200","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/01.jcp.0000239790.83707.ab","article-title":"A double-blind comparison between bupropion XL and venlafaxine XR: Sexual functioning, antidepressant efficacy, and tolerability","volume":"26","author":"Thase","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"2023010713375390400_bb0205","article-title":"The effect of vortioxetine on sexual dysfunction during the treatment of adults with major depressive disorder (MDD) or generalized anxiety disorder (GAD) [abstract]","author":"Jacobsen","year":"2014","journal-title":"Poster presented at 54th Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP\/NCDEU), June 16\u201319"},{"key":"2023010713375390400_bb0210","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/hup.2424","article-title":"A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin\u2013noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine","volume":"29","author":"Montgomery","year":"2014","journal-title":"Hum Psychopharmacol"},{"key":"2023010713375390400_bb0215","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/01.yic.0000074988.54339.7c","article-title":"Escitalopram (10\u201320\u2009mg\/day) is effective and well tolerated in a placebo-controlled study in depression in primary care","volume":"18","author":"Lepola","year":"2003","journal-title":"Int Clin Psychopharmacol"},{"key":"2023010713375390400_bb0220","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/00004850-200205000-00001","article-title":"Escitalopram 10\u2009mg\/day is effective and well tolerated in a placebo-controlled study in depression in primary care","volume":"17","author":"Wade","year":"2002","journal-title":"Int Clin Psychopharmacol"},{"key":"2023010713375390400_bb0225","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1017\/S1461145704004365","article-title":"Escitalopram dose-response revisited: An alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression","volume":"7","author":"Bech","year":"2004","journal-title":"Int J Neuropsychopharmacol"},{"key":"2023010713375390400_bb0230","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.4088\/JCP.v67n1115","article-title":"Escitalopram maintenance treatment for prevention of recurrent depression: A randomized, placebo-controlled trial","volume":"67","author":"Kornstein","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"2023010713375390400_bb0235","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.pharmthera.2014.07.001","article-title":"Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data","volume":"145","author":"Sanchez","year":"2015","journal-title":"Pharmacol Ther"},{"key":"2023010713375390400_bb0240","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00213-006-0666-y","article-title":"Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: An [123I]ADAM SPECT study","volume":"191","author":"Klein","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"2023010713375390400_bb0245","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/bjp.2008.243","article-title":"Prediction of clinical response based on pharmacokinetic\/pharmacodynamic models of 5-hydroxytryptamine reuptake inhibitors in mice","volume":"155","author":"Kreilgaard","year":"2008","journal-title":"Br J Pharmacol"},{"key":"2023010713375390400_bb0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2013.00045","article-title":"Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: A review of the clinical evidence and the possible mechanisms involved","volume":"4","author":"Renoir","year":"2013","journal-title":"Front Pharmacol"},{"key":"2023010713375390400_bb0255","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/0269881105056666","article-title":"Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine","volume":"20","author":"Baldwin","year":"2006","journal-title":"J Psychopharmacol"},{"key":"2023010713375390400_bb0260","first-page":"256841","article-title":"Reduced treatment-emergent sexual dysfunction as a potential target in the development of new antidepressants","volume":"2013","author":"Baldwin","year":"2013","journal-title":"Depress Res Treat"},{"key":"2023010713375390400_bb0265","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1177\/0269881112441866","article-title":"A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder","volume":"26","author":"Boulenger","year":"2012","journal-title":"J Psychopharmacol"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515344192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515344192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/12\/10\/2036\/48475948\/jsm_12_10_2036.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/12\/10\/2036\/48475948\/jsm_12_10_2036.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T14:43:27Z","timestamp":1675953807000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/12\/10\/2036\/6966801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,1]]},"references-count":52,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2015,10,1]]},"published-print":{"date-parts":[[2015,10,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jsm.12980","relation":{},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2015,10]]},"published":{"date-parts":[[2015,10,1]]}}}